ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company listed on Nasdaq under the ticker ORIC, has announced participation in two key investor conferences in June 2024. The company's management will appear at the Jefferies Global Healthcare Conference on June 5 at 10:30 a.m. ET and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 10:40 a.m. ET. Webcasts of these discussions will be available on the company's website, with replays accessible for 90 days following the events.

Positive

• Participation in high-profile investor conferences can increase visibility and investor interest.
• Availability of webcast replays extends access to presentations for a broader audience.

Negative

• No new financial or clinical data was disclosed, thus immediate impact on stock valuation.
• Investor conferences are routine events and may not significantly move the stock without substantive updates.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June:

• Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 5, 2024, at 10:30 a.m. ET.

• Goldman Sachs 45^th Annual Global Healthcare Conference – Participating in a fireside chat on Monday, June 10, 2024, at 10:40 a.m. ET.
  

Webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What investor conferences will ORIC Pharmaceuticals participate in June 2024?

ORIC Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10.

When is ORIC Pharmaceuticals scheduled to present at the Jefferies Global Healthcare Conference?

ORIC Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 10:30 a.m. ET.

How can I access the webcasts of ORIC Pharmaceuticals' investor conference presentations?

The webcasts will be available on the investor section of ORIC Pharmaceuticals' website, with replays accessible for 90 days after the events.

When is ORIC Pharmaceuticals scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference?

ORIC Pharmaceuticals will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 10:40 a.m. ET.